

1 **Immunogenicity of Oxford-AstraZeneca COVID-19 vaccine in**
2 **Vietnamese healthcare workers**

3 Nguyen Van Vinh Chau¹, Lam Anh Nguyet², Nguyen Thanh Truong¹, Le Mau Toan¹,
4 Nguyen Thanh Dung¹, Le Manh Hung¹, Mai Thanh Nhan¹, Dinh Nguyen Huy Man¹,
5 Nghiem My Ngoc¹, Huynh Phuong Thao¹, Tran Nguyen Hoang Tu¹, Huynh Kim Mai³, Do
6 Thai Hung³, Nguyen Thi Han Ny², Le Kim Thanh², Nguyen To Anh², Nguyen Thi Thu
7 Hong², Le Nguyen Truc Nhu², Lam Minh Yen², Marc Choisy^{2,4}, Tran Tan Thanh², Guy
8 Thwaites^{2,3} and Le Van Tan², for OUCRU COVID-19 Research Group*

9 ¹Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

10 ²Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam

11 ³Institute of Pasteur, Nha Trang City, Vietnam

12 ⁴Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
13 University of Oxford, Oxford, UK

*Members of the groups are listed in the acknowledgments.

14 Correspondence: Nguyen Van Vinh Chau, chaunvv@oucru.org, Le Van Tan,
15 tanlv@oucru.org

16 **Word count: abstract:** 49 **Main text:** 1465

17 **Running title:** Immunogenicity and safety of Oxford-AstraZeneca COVID-19 vaccine,
18 Vietnam

19 **Keywords:** COVID-19, SARS-CoV-2, vaccine, pandemic, Vietnam

20 **ABSTRACT**

21 We studied the immunogenicity of Oxford-AstraZeneca COVID-19 vaccine in 554
22 Vietnamese healthcare workers who were naïve to SARS-CoV-2 infection. Neutralizing
23 antibodies increased after each dose. The sero-conversion rate reached 98.1% after dose 2.
24 But at month 3, neutralizing antibodies decreased. The requirement for a third dose
25 warrants further research.

26 Vaccination is critical to bring COVID-19 under control. Although a vaccine must fulfill
27 the required efficacy criteria in order to receive an approval for use in humans, the rapid
28 development and deployment of COVID-19 vaccines worldwide necessitate follow up
29 studies to better understand the development and persistence of vaccine-induced immunity
30 in different populations. Such knowledge is critical to inform the global vaccination
31 strategies and the development of next-generation vaccines.

32 Vietnamese people remains relatively naïve to SARS-CoV-2 infections [1, 2]; as of 5th July
33 2021, 19,579 PCR confirmed cases have been reported in a population of >97 million.
34 Therefore Vietnam is an ideal setting for vaccine evaluation study as the results naturally
35 reflect the immunity induced by COVID-19 vaccines. There has been no report about the
36 immunogenicity of the Oxford-AstraZeneca COVID-19 vaccine from Southeast Asia. We
37 studied the immunogenicity of Oxford-AstraZeneca COVID-19 vaccine in a cohort of 554
38 healthcare workers of an infectious diseases hospital in southern Vietnam.

39 **METHODS**

40 **Setting**

41 The present study was conducted at the Hospital for Tropical Diseases (HTD) in HCMC.
42 HTD is a 660-bed tertiary referral hospital for patients with infectious diseases (including
43 COVID-19) in southern Vietnam [3]. According to the MOH criteria (Supplementary
44 Materials), HTD members of staff were eligible for vaccination and were the first in
45 Vietnam to receive a COVID-19 vaccine in March 2021.

46 **Data collection**

47 We collected demographics and 3ml of blood from the study participants. Blood sampling
48 was scheduled for 7 time points, including before each dose, 14 days after each dose, and

49 month 1, 3, 6 and 12 after vaccination. After day 28 of the first dose, blood sampling was
50 narrowed down to a subgroup of 144 individuals randomly selected from the study
51 participants for subsequent follow up. The present report focused on the period from
52 baseline to month 3 after the first dose.

53 **Neutralizing antibody measurement**

54 Neutralizing antibodies were measured using an FDA EUA approved assay, namely
55 SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) (GenScript, USA) [4],
56 following to the manufacturer's instructions (Supplementary Materials).

57 We also included neutralizing antibody data from 11 Vietnamese individuals with
58 asymptomatic or mild SARS-CoV-2 infection for comparative analysis (Supplementary
59 Materials) [5].

60 **Statistical analysis**

61 We used Fisher exact, χ^2 or Mann-Whitney U test to compare between groups (when
62 appropriate). Logistic regression was used to assess association between the probability of
63 having detectable neutralizing antibodies and age. Linear regression was used to assess the
64 association between neutralizing antibodies levels and age. The analyses were carried
65 using Prism 9.0.2 (graphpad.com).

66 **Ethics**

67 The study was approved by the Institutional Review Board of HTD and the Oxford
68 Tropical Research Ethics Committee, University of Oxford, UK. Written informed
69 consents were obtained all the participants.

70 **RESULTS**

71 **Demographics of the study participants**

72 A total 649/894 (73%) HTD staff consented to participate in the vaccine evaluation study.
73 554/649 (85%) participants were successfully followed-up up to day 28 after the first dose
74 and were thus included for analysis as whole group. The 554 study participants aged
75 between 24 and 65 years (median: 37 years). Females were predominant (Supplementary
76 Table 1)

77 Of the 144 participants of the subgroup, 104 (72%) and 95 (66%) were successfully
78 followed-up up to 14 after the second dose and month 3 after the first dose, respectively.
79 The age and gender distributions of these subgroups were comparable with that of the
80 whole group (Supplementary Table 1). The window time between the first and the second
81 dose was six weeks.

82 **Development of detectable neutralizing antibodies**

83 Because HTD members of staff were naïve to SARS-CoV-2 infection [1], we first focused
84 our neutralizing antibody measurement on the baseline samples collected before the first
85 dose of the subgroup. At baseline, none of the study participants had detectable
86 neutralizing antibodies (Supplementary Table 2). At day 14 and 28 after the first dose, the
87 proportions of the study participants with detectable neutralizing antibodies increased from
88 27.3% (151/554) to 78.0% (432/554), respectively among all 554 individuals of the whole
89 group. The proportion of the study participants with detectable neutralizing antibodies
90 reached 98.1% (102/104) at 14 days after the second dose, and then slightly dropped to
91 94.7% (90/95) at month 3 after the first dose (i.e. six weeks after the second dose)
92 (Supplementary Table 2).

93 **Kinetics of neutralizing antibody levels**

94 Neutralizing antibody levels measured at day 28 after the first dose were significantly
95 higher than that measured at day 14 (Figure 1A), but comparable with that measured at 6
96 weeks (Figure 1B). At day 14 after the second dose, neutralizing antibodies significantly
97 increased, and were comparable with that obtained from Vietnamese people with
98 asymptomatic or mild infection (Figure 1B). At month 3 after the first dose neutralizing
99 antibody levels were significantly lower than that measured at 14 days after the second
100 dose (Figure 1B)

101 **Neutralizing antibodies vs. age and gender**

102 At day 14 after the first dose, the development and levels of detectable neutralizing
103 antibodies among 554 study participants were negatively correlated with age. This
104 difference was less profound at day 28, especially with regard to the development of
105 detectable neutralizing antibodies (Figure 1C&D). At these corresponding time points,
106 similar trends were also observed among individuals of the subgroup, but the difference
107 was not significant (Supplementary Figure 1&2), likely because of the small sample size.
108 At 14 days after the second dose and month 3 after the first dose, the proportion of
109 individuals with detectable neutralizing antibodies was similar across age groups
110 (Supplementary Figure 1B&C).

111 With the exception of day 28 after the first dose, neutralizing antibody levels and the
112 proportion of study participants with detectable neutralizing antibodies were comparable
113 between males and females (Supplementary Table 2 and Supplementary Figure 3).

114 **DISCUSSION**

115 We report the immunogenicity of Oxford-AstraZeneca COVID-19 vaccine in a cohort of
116 554 Vietnamese healthcare workers who were naïve to SARS-CoV-2 infection. We
117 showed that Oxford-AstraZeneca COVID-19 vaccine is immunogenic. At month 3 after
118 the first dose, neutralizing antibody levels reduced significantly, while the seroconversion
119 rate slightly declined from 98.1% at day 14 after the second dose to 94.7%.

120 Findings from the original phase 2/3 trial showed that spike protein specific IgG developed
121 within two weeks after vaccination, and at 14 days after the second dose its titers increased
122 with a seroconversion rate of 208/209 (>99%) [6]. Consistently, our study showed the
123 development and the levels of neutralizing antibodies significantly increases after each
124 dose, with the former reaching 98% at 14 days after the second dose. Parallel with these
125 reports are real-world data from the UK showing that the administration of the second dose
126 increased protection against SARS-CoV-2 infection from 65% by dose 1 to 70% by dose 2
127 among vaccine recipients [7]. A single dose of Oxford-AstraZeneca or Pfizer COVID-19
128 vaccines reduced COVID-19 hospital admissions among vaccine recipients by 88% and
129 91%, respectively in Scotland [8].

130 Older individuals, especially those 80 years or above, without prior infection had lower
131 levels of neutralizing antibodies induced by the first dose than younger adults [9, 10].
132 These age-dependent responses were most profound within the first 3 weeks after
133 vaccination, but were resolved by the administration of the second dose [9]. Although
134 similar trends were observed in our study, at day 28 after the first dose, the differences in
135 our study were negligible, especially in terms of the seroconversion rate. None of our study
136 participant was older than 71 years, explaining why the observed differences were less
137 profound as compared to the UK population based study.

138 The results provide reassuring evidence for the effectiveness of the proposed vaccination
139 strategy aiming at prioritizing the first dose for as many people as possible in the first
140 instance [11]. However, our results also emphasize the importance of the second dose,
141 especially in older people, while it remains unknown whether the third dose is needed to
142 provide long-term protection. A decline in antibody titers was recorded at week 8-12 after
143 the first two doses among 75 study participants in the UK [12]. But the administration of
144 the third dose helped boost the immune response. Antibody waning is presumably more
145 profound among individuals without prior infection. Follow study is therefore critical to
146 assess the levels of antibody waning among our study participants.

147 Our study has some limitations. We did not study cellular immunity, especially T cell
148 response. And due to the age and gender structure in nature of HTD staff, we did not
149 include participants older than 71 years and females were predominant among our study
150 subjects. Compared with males, females seemed to better respond to Oxford-AstraZeneca
151 COVID-19 vaccine at day 28 after the first dose, which warrants further research.

152 **CONCLUSIONS**

153 Oxford-AstraZeneca COVID-19 vaccine is immunogenic in Vietnamese healthcare
154 workers who were naïve to SARS-CoV-2 infection. Neutralizing antibody levels decreased
155 at month 3 after vaccination. The requirement for a third dose warrants further research.
156 These data are critical to informing the deployment of COVID-19 vaccine in Vietnam and
157 other Southeast Asian countries.

158 **ACKNOWLEDGEMENTS**

159 This study was funded by the Wellcome Trust of Great Britain (106680/B/14/Z and
160 204904/Z/16/Z) and NIH/NIAID (HHSN272201400007C, Subcontract No. S000596-
161 JHU)..

162 We thank our colleagues at the Hospital for Tropical Diseases in Ho Chi Minh City,
163 Vietnam for their participations in this study.

164 **OUCRU COVID-19 Research Group**

165 **Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam:** Nguyen Van Vinh Chau,
166 Nguyen Thanh Dung, Le Manh Hung, Huynh Thi Loan, Nguyen Thanh Truong, Nguyen
167 Thanh Phong, Dinh Nguyen Huy Man, Nguyen Van Hao, Duong Bich Thuy, Nghiem My
168 Ngoc, Nguyen Phu Huong Lan, Pham Thi Ngoc Thoa, Tran Nguyen Phuong Thao, Tran
169 Thi Lan Phuong, Le Thi Tam Uyen, Tran Thi Thanh Tam, Bui Thi Ton That, Huynh Kim
170 Nhung, Ngo Tan Tai, Tran Nguyen Hoang Tu, Vo Trong Vuong, Dinh Thi Bich Ty, Le
171 Thi Dung, Thai Lam Uyen, Nguyen Thi My Tien, Ho Thi Thu Thao, Nguyen Ngoc Thao,
172 Huynh Ngoc Thien Vuong, Huynh Trung Trieu Pham Ngoc Phuong Thao, Phan Minh
173 Phuong

174 **Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam:** Dong Thi
175 Hoai Tam, Evelyne Kestelyn, Donovan Joseph, Ronald Geskus, Guy Thwaites, Ho Quang
176 Chanh, H. Rogier van Doorn, Ho Van Hien, Ho Thi Bich Hai, Huynh Le Anh Huy, Huynh
177 Ngan Ha, Huynh Xuan Yen, Jennifer Van Nuil, Jeremy Day, Joseph Donovan, Katrina
178 Lawson, Lam Anh Nguyet, Lam Minh Yen, Le Dinh Van Khoa, Le Nguyen Truc Nhu, Le
179 Thanh Hoang Nhat, Le Van Tan, Sonia Lewycka Odette, Louise Thwaites, Maia Rabaa,
180 Marc Choisy, Mary Chambers, Motiur Rahman, Ngo Thi Hoa, Nguyen Thanh Thuy Nhien,
181 Nguyen Thi Han Ny, Nguyen Thi Kim Tuyen, Nguyen Thi Phuong Dung, Nguyen Thi Thu
182 Hong, Nguyen Xuan Truong, Phan Nguyen Quoc Khanh, Phung Le Kim Yen, Phung Tran
183 Huy Nhat, Sophie Yacoub, Thomas Kesteman, Nguyen Thuy Thuong Thuong, Tran Tan
184 Thanh, Tran Tinh Hien, Vu Thi Ty Hang

REFERENCES


- 185 1. Chau, N.V.V., et al., *Absence of SARS-CoV-2 antibodies in health care workers of*
186 *a tertiary referral hospital for COVID-19 in southern Vietnam*. *Journal of*
187 *Infection*, 2021. **82**(1): p. e36-e37.
- 188 2. Van Tan, L., *COVID-19 control in Vietnam*. *Nat Immunol*, 2021. **22**(3): p. 261.
- 189 3. Chau, N.V.V., et al., *The natural history and transmission potential of*
190 *asymptomatic SARS-CoV-2 infection*. *Clin Infect Dis*, 2020.
- 191 4. Tan, C.W., et al., *A SARS-CoV-2 surrogate virus neutralization test based on*
192 *antibody-mediated blockage of ACE2-spike protein-protein interaction*. *Nat*
193 *Biotechnol*, 2020. **38**(9): p. 1073-1078.
- 194 5. Mai, H.K., et al., *Long-Term Humoral Immune Response in Persons with*
195 *Asymptomatic or Mild SARS-CoV-2 Infection, Vietnam*. *Emerg Infect Dis*, 2021.
196 **27**(2): p. 663-666.
- 197 6. Folegatti, P.M., et al., *Safety and immunogenicity of the ChAdOx1 nCoV-19*
198 *vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind,*
199 *randomised controlled trial*. *The Lancet*, 2020. **396**(10249): p. 467-478.
- 200 7. Pritchard, E., et al., *Impact of vaccination on SARS-CoV-2 cases in the community:*
201 *a population-based study using the UK's COVID-19 Infection Survey*. *MedRxiv*,
202 2021.
- 203 8. Vasileiou, E., et al., *Interim findings from first-dose mass COVID-19 vaccination*
204 *roll-out and COVID-19 hospital admissions in Scotland: a national prospective*
205 *cohort study*. *The Lancet*, 2021. **397**(10285): p. 1646-1657.
- 206 9. Wei, J., et al., *The impact of SARS-CoV-2 vaccines on antibody responses in the*
207 *general population in the United Kingdom*. *MedRxiv*, 2021.
- 208 10. Abu Jabal, K., et al., *Impact of age, ethnicity, sex and prior infection status on*
209 *immunogenicity following a single dose of the BNT162b2 mRNA COVID-19*
210 *vaccine: real-world evidence from healthcare workers, Israel, December 2020 to*
211 *January 2021*. *Euro Surveill*, 2021. **26**(6).
- 212 11. Romero-Brufau, S., et al., *Public health impact of delaying second dose of*
213 *BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling*
214 *study*. *BMJ*, 2021. **373**: p. n1087.
- 215 12. Flaxman, A., et al., *Tolerability and Immunogenicity After a Late Second Dose or a*
216 *Third Dose of ChAdOx1 nCoV-19 (AZD1222)*. Preprint with *Lancet*,
217 <http://dx.doi.org/10.2139/ssrn.3873839>.

218 **LEGENDS TO FIGURES**

219 **Figure 1:** Development of neutralizing antibodies levels and their associations with age;
220 **A)** Neutralizing antibody levels measured at 14 and 28 days after the first dose of 554
221 study participants; **B)** Neutralizing antibody levels measured at time points from baseline
222 to month 3 after the first dose of the subgroups; **C)** Association between age and the
223 probabilities of having detectable neutralizing antibodies at 14 and 28 days after the first
224 dose of 554 study participants; **D)** Association between age and neutralizing antibody
225 levels measured at 14 and 28 days after the first dose of 554 study participants

226 **Notes to figure 1B:** Data on neutralizing antibody levels obtained from 11 convalescent
227 sera collected at week 4-7 (last column) from cases with mild or asymptomatic infection
228 was included as references. Black circles: data for 2 week time point and grey circles: data
229 for 4 week time point

Figure 1



230 **Immunogenicity of Oxford-AstraZeneca COVID-19 vaccine in**
231 **Vietnamese healthcare workers**

232 Nguyen Van Vinh Chau¹, Lam Anh Nguyet², Nguyen Thanh Truong¹, Le Mau Toan¹,
233 Nguyen Thanh Dung¹, Le Manh Hung¹, Mai Thanh Nhan¹, Dinh Nguyen Huy Man¹,
234 Nghiem My Ngoc¹, Huynh Phuong Thao¹, Tran Nguyen Hoang Tu¹, Huynh Kim Mai³, Do
235 Thai Hung³, Nguyen Thi Han Ny², Le Kim Thanh², Nguyen To Anh², Nguyen Thi Thu
236 Hong², Le Nguyen Truc Nhu², Lam Minh Yen², Marc Choisy^{2,4}, Tran Tan Thanh², Guy
237 Thwaites^{2,3} and Le Van Tan², for OUCRU COVID-19 Research Group*

238 ¹Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

239 ²Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam

240 ³Institute of Pasteur, Nha Trang City, Vietnam

241 ⁴Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
242 University of Oxford, Oxford, UK

*Members of the groups are listed in the acknowledgments.

243 Correspondence: Nguyen Van Vinh Chau, chaunvv@oucru.org, Le Van Tan,
244 tanlv@oucru.org

245 **COVID-19 vaccine rollout in Vietnam**

246 Vietnam received the first 117,000 doses of Oxford-AstraZeneca COVID-19 vaccine in
247 early March 2021. High-risk groups, especially frontline healthcare workers, were
248 prioritized for vaccination. The window time between two doses was set for 4 weeks, with
249 some variation depending on the availability of the vaccine.

250 **List of groups prioritized for COVID-19 vaccination in Vietnam**

- 251 1. Frontline healthcare workers of COVID-19, including people whose work is to deal
252 with COVID-19 prevention and control work (members of COVID-19 steering
253 committees at all levels, staff at state-run quarantine sites, people conducting
254 contract tracing and epidemiological investigations, volunteers, reporters among
255 others), military and public security forces
- 256 2. Vietnamese diplomats, customs and immigration officers
- 257 3. Essential service workers in sectors such as aviation, transport, tourism, electricity
258 and water supply
- 259 4. Teachers and individuals working at education and training facilities, and those
260 working at State agencies with regular contact with various people
- 261 5. People with chronic diseases or aging above 65
- 262 6. Residents in outbreak hotspots in Vietnam
- 263 7. Poor people, Policy beneficiaries
- 264 8. Those who will be sent abroad for learning and working
- 265 9. Other people determined by the Ministry of Health

266 **Measurements of neutralizing antibody using Surrogate virus neutralization assay**

267 Surrogate virus neutralization assay (sVNT) is an assay that measures spike protein
268 receptor binding domain (RBD)-targeting neutralizing antibodies (RBD-targeting NAbs)
269 Prior to testing, plasma samples were first diluted 1:10 and then inactivated at 56⁰C for 30
270 minutes. The experiments were carried out according the manufacturer's instruction. The
271 obtained results were expressed as percentage of inhibition with the 30% cut-off applied.
272 The percentage of inhibition measured by sVNT has been shown to well correlate with the
273 neutralizing antibody tiers measured by the conventional plaque reduction neutralization
274 assay [1].

275 **Neutralizing antibody data from cases of natural infection**

276 To compare the development of neutralizing antibodies induced by vaccination against that
277 of natural infection, we included data from 11 Vietnamese patients who had mild or
278 asymptomatic infections. Details about these individuals and neutralizing antibody
279 measurement were detailed in our recent report [2].

280 **References**

- 281 1. Tan, C.W., et al., *A SARS-CoV-2 surrogate virus neutralization test based on*
282 *antibody-mediated blockage of ACE2-spike protein-protein interaction*. Nat
283 Biotechnol, 2020. **38**(9): p. 1073-1078.
- 284 2. Mai, H.K., et al., *Long-Term Humoral Immune Response in Persons with*
285 *Asymptomatic or Mild SARS-CoV-2 Infection, Vietnam*. Emerg Infect Dis, 2021.
286 **27**(2): p. 663-666.


Supplementary Table 1: Demographics of the study participants

	Whole group (N=554)	Subgroup (N=104)	Subgroup (N=95)
Male, n (%)	136 (25)	25 (24)	21 (22)
Female, n (%)	418 (75)	79 (76)	73 (78)
Median age in years (range)	36 (22 – 71)	37 (24 – 65)	37 (24-65)
Age groups			
20-39, n (%)	332 (60)	57 (55)	50 (53)
40-60, n (%)	217 (39)	46 (44)	43 (46)
61-71, n (%)	5 (1)	1 (1)	1 (1)


Supplementary Table 2: The proportion of study participants with detectable neutralizing antibodies after vaccination

Time point	Whole group				Subgroup			
	Total (N=554)	Male (N=136)	Female (N=418)	P value*	Total (N=104)	Male (N=25)	Female (N=79)	P value*
Baseline, n (%)	0	0	0	NA	0	0	0	NA
14 days after dose 1, n (%)	151 (27.3)	40 (29.4)	111 (26.6)	0.52	31 (29.8)	10 (40.0)	21 (26.6)	0.20
28 days after dose 1, n (%)	432 (78.0)	97 (71.3)	335 (80.1)	0.031	82 (78.8)	20 (80.0)	62 (78.5)	0.87
Before dose 2, n (%)	N/A	N/A	N/A	N/A	73 (70.2)	17 (68.0)	56 (70.1)	0.78
14 days after dose 2, n (%)	N/A	N/A	N/A	N/A	102 (98.1)	24 (96.0)	78 (98.7)	0.43
Month 3 after the first dose**	NA	NA	NA	NA	89 (94.7)	68 (95.5)	21 (95.5)	1


Notes to Supplementary Table 2: *for comparison between males and females, NA: non-applicable, ** n=95 (male: 22 and females: 72)



Supplementary Figure 1: Probability of having detectable neutralizing antibodies among the study participants selected for assessment of the impact of the second dose. **A)** At 2 and 4 weeks after the first dose ($n=104$), **B)** Before the second dose (i.e. 6 weeks after the first dose) and 2 weeks after the second dose ($n=104$) and **C)** at month 3 after the first dose ($n=95$)



Supplementary Figure 2: Neutralizing antibody levels of participants selected for assessment of the impact of the second dose. **A)** At 2 and 4 weeks after the first dose (n=104), **B)** Before the second dose (i.e. 6 weeks after the first dose) and 2 weeks after the second dose (n=104) and **C)** at month 3 after the first dose (n=95)



Supplementary Figure 3: Association between neutralizing antibody levels and gender. **A)** At 2 and 4 weeks after the first dose of the whole group (n=554), **B)** From baseline to month three after the first dose of the subgroup